Filing Flows › Zoetis (ZTS) › Q2 2026
Zoetis (ZTS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Zoetis (ZTS) reported revenue of $2.5B for the second quarter 2026 (Q2 2026), -0.2% from a year earlier and +9% from the quarter before. Operating margin was 35.1%, net earnings $691M (28.0% of revenue).
Zoetis, Q2 2026: revenue $2.5B (-0.2% year over year), operating margin 35.1%, net earnings $691M, operating cash flow $655M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5B | +9% | -0.2% |
| Operating profit | $866M | +14% | -5% |
| Net earnings | $691M | +15% | -5% |
| Operating cash flow | $655M | +63% | +8% |
| Free cash flow | $538M | +85% | +17% |
What changed
Revenue was $2.5B in Q2 2026, roughly flat year over year and up 9% from the previous quarter. Parasiticides was the largest line at 28% of revenue. Dermatology lost $0.07B year over year (down 16%), 1250% of the total change.
Operating profit was $0.87B, a 35.1% margin (down 1.8 points year over year). Total costs grew 3% against flat revenue. The fastest-growing cost line was Other operating costs (+39%). Net earnings were $0.69B, down 5% year over year. The effective tax rate was 20.2%.
Operating cash flow was $0.66B (up 8% year over year), 95% of net earnings. Non-cash charges added back $0.12B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items used $0.18B. Capital expenditures of $0.12B left free cash flow of $0.54B.
Questions
What was Zoetis' revenue in the second quarter 2026?
Zoetis (ZTS) reported revenue of $2.5B for the second quarter 2026 (Q2 2026), -0.2% from a year earlier and +9% from the quarter before.
Was Zoetis profitable in the second quarter 2026?
Operating profit was $866M (35.1% of revenue) and net earnings $691M.
Source: Zoetis 10-Q on SEC EDGAR.